Cardiology Updates Rosemont

Rosemont, IL | October 9, 2018

Donald E. Stephens Convention Center

Translating Evidence to Practice: Improving Outcomes in Patients with ASCVD with PCSK9 Inhibitors


Through patient cases, the faculty will discuss the latest evidence, indications, and guideline-based utilization of PCSK9 inhibitors to lower LDL-C and overall cardiovascular risk in patients with acquired and familial hypercholesterolemia. This session will also provide strategies to overcome denial of PCSK9 inhibitors by payers and implement a team-based approach to improve patient access.

Learning Objectives

Assess the safety and efficacy of PCSK9 inhibitors in reducing cardiovascular events in patients with acute coronary syndrome and hypercholesterolemia

Review current evidence and set optimal LDL-C targets for patients with documented ASCVD

Appropriately integrate PCSK9 inhibitors in clinical practice to reduce the risk of cardiovascular events in high-risk patients

Identify common reasons for PCSK9 inhibitor denial and implement a team-based approach to improve patient access


Download a PDF of presented slides.



Douglas Jacoby, MD, FACC, FNLA

Douglas S. Jacoby, MD, FACC, is an Associate Professor of Clinical Medicine at the Perelman School of Medicine at the University of Pennsylvania. He serves as the medical director of the Penn Medicine Center for Preventive Cardiology at the Philadelp...

View Full Bio

Ty J. Gluckman, MD, FACC, FAHA

Ty J. Gluckman, MD, FACC, FAHA, is medical director of the Center for Cardiovascular Analytics, Research, and Data Science (CARDS) at the Providence St. Joseph Heart Institute in Portland, Oregon and an adjunct faculty member of the Ciccarone Center ...

View Full Bio

Educational Partners

Horizon CME

Commercial Supporters

Sanofi US and Regeneron Pharmaceuticals